Document Detail

Long-term outcome of treatment with ruxolitinib in myelofibrosis.
MedLine Citation:
PMID:  21995409     Owner:  NLM     Status:  In-Data-Review    
The initial encouraging activity of ruxolitinib in myelofibrosis appears to need some caveats when long-term efficacy is examined. The control of splenomegaly may not be durable, and the likelihood of leukemic progression or death is not dramatically lowered.
Ayalew Tefferi; Mark R Litzow; Animesh Pardanani
Related Documents :
19618979 - Composition of the council of representatives: report on the apportionment ballot for r...
15495129 - Antifibrinolytic drugs for acute traumatic injury.
11503999 - Benchmarking the endodontic literature on medline.
10830739 - A comparison of elderly patients with aggressive histology lymphoma who were entered or...
20536689 - Multi-centre assessment of mycotic rhinosinusitis in dogs: a retrospective study of ini...
20826029 - A prospective, randomized, multi-center trial to investigate actovegin in prevention an...
15736749 - Brachial plexus palsy secondary to birth injuries.
3764689 - Revision of failed infrainguinal bypass graft: principles of management.
21434729 - The effect of laser-activated acidulated phosphate fluoride on enamel submitted to eros...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  365     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1455-7     Citation Subset:  AIM; IM    
Mayo Clinic, Rochester, MN
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The avastin story.
Next Document:  Myotonia of the tongue.